Pyxis Oncology, Inc. Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities
Pyxis Oncology, Inc. (PYXS) reported Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities of $3.83 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities · last filed 2026-08-13
- Pyxis Oncology, Inc. increase (decrease) in accrued liabilities and other operating liabilities for the quarter ending 2026-06-30 was $2.60M.
- Pyxis Oncology, Inc. increase (decrease) in accrued liabilities and other operating liabilities for the quarter ending 2026-03-31 was $1.23M.
- Pyxis Oncology, Inc. increase (decrease) in accrued liabilities and other operating liabilities for the quarter ending 2025-12-31 was $552.00K.
- Pyxis Oncology, Inc. increase (decrease) in accrued liabilities and other operating liabilities for the quarter ending 2025-09-30 was $1.30M, a 67.29% decline year-over-year.
- Pyxis Oncology, Inc. increase (decrease) in accrued liabilities and other operating liabilities for fiscal 2025 was -$2.82M.
- Pyxis Oncology, Inc. increase (decrease) in accrued liabilities and other operating liabilities for fiscal 2024 was -$1.67M.
- Pyxis Oncology, Inc. increase (decrease) in accrued liabilities and other operating liabilities for fiscal 2023 was -$14.10M, a 217.96% decline from fiscal 2022.
- Pyxis Oncology, Inc. increase (decrease) in accrued liabilities and other operating liabilities for fiscal 2022 was $11.95M, a 134.70% increase from fiscal 2021.
| Period end | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 3 month | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 3 month as first filed | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 6 month | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 9 month | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | $2.60M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $3.83M 10-Q · filed 2026-08-13 | $4.38M derived: sum of 3 quarters · filed 2026-08-13 | $5.68M derived: sum of 4 quarters · filed 2026-08-13 | |
| 2026-03-31 | $1.23M 10-Q · filed 2026-05-14 | $1.78M derived: sum of 2 quarters · filed 2026-05-14 | $3.08M derived: sum of 3 quarters · filed 2026-05-14 | -$296.00K derived: sum of 4 quarters · filed 2026-08-13 | |
| 2025-12-31 | $552.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-23 | $1.85M derived: sum of 2 quarters · filed 2026-03-23 | -$1.53M derived: sum of 3 quarters · filed 2026-08-13 | -$2.82M 10-K · filed 2026-03-23 | |
| 2025-09-30 | $1.30M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-03 | -$2.08M derived: sum of 2 quarters · filed 2026-08-13 | -$3.38M 10-Q · filed 2025-11-03 | -$6.06M derived: sum of 4 quarters · filed 2026-08-13 | |
| 2025-06-30 | -$3.38M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | -$4.67M 10-Q · filed 2026-08-13 | -$7.36M derived: sum of 3 quarters · filed 2026-08-13 | -$3.39M derived: sum of 4 quarters · filed 2026-08-13 | |
| 2025-03-31 | -$1.29M 10-Q · filed 2026-05-14 | -$1.31M 10-Q · filed 2025-05-15 | -$3.98M derived: sum of 2 quarters · filed 2026-05-14 | -$14.00K derived: sum of 3 quarters · filed 2026-05-14 | -$822.00K derived: sum of 4 quarters · filed 2026-05-14 |
| 2024-12-31 | -$2.69M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-23 | $1.28M derived: sum of 2 quarters · filed 2026-03-23 | $473.00K derived: sum of 3 quarters · filed 2026-03-23 | -$1.67M 10-K · filed 2026-03-23 | |
| 2024-09-30 | $3.97M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-03 | $3.16M derived: sum of 2 quarters · filed 2025-11-03 | $1.02M 10-Q · filed 2025-11-03 | -$2.65M derived: sum of 4 quarters · filed 2025-11-03 | |
| 2024-06-30 | -$808.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | -$2.95M 10-Q · filed 2025-08-14 | -$6.61M derived: sum of 3 quarters · filed 2025-08-14 | -$5.90M derived: sum of 4 quarters · filed 2025-08-14 | |
| 2024-03-31 | -$2.14M 10-Q · filed 2025-05-15 | -$5.80M derived: sum of 2 quarters · filed 2025-05-15 | -$5.09M derived: sum of 3 quarters · filed 2025-05-15 | -$2.97M derived: sum of 4 quarters · filed 2025-05-15 | |
| 2023-12-31 | -$3.66M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-18 | -$2.95M derived: sum of 2 quarters · filed 2025-03-18 | -$824.00K derived: sum of 3 quarters · filed 2025-03-18 | -$14.10M 10-K · filed 2025-03-18 | |
| 2023-09-30 | $712.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $2.84M derived: sum of 2 quarters · filed 2024-11-12 | -$10.44M 10-Q · filed 2024-11-12 | -$4.12M derived: sum of 4 quarters · filed 2024-11-12 | |
| 2023-06-30 | $2.13M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | -$11.15M 10-Q · filed 2024-08-14 | -$4.83M derived: sum of 3 quarters · filed 2024-08-14 | $300.00K derived: sum of 4 quarters · filed 2024-08-14 | |
| 2023-03-31 | -$13.27M 10-Q · filed 2024-05-14 | -$6.96M derived: sum of 2 quarters · filed 2024-05-14 | -$1.83M derived: sum of 3 quarters · filed 2024-05-14 | -$11.86M derived: sum of 4 quarters · filed 2024-05-14 | |
| 2022-12-31 | $6.32M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-21 | $11.45M derived: sum of 2 quarters · filed 2024-03-21 | $1.41M derived: sum of 3 quarters · filed 2024-03-21 | $11.95M 10-K · filed 2024-03-21 | |
| 2022-09-30 | $5.13M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | -$4.90M derived: sum of 2 quarters · filed 2023-11-07 | $5.64M 10-Q · filed 2023-11-07 | $7.56M derived: sum of 4 quarters · filed 2023-11-07 | |
| 2022-06-30 | -$10.04M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-11 | $504.00K 10-Q · filed 2023-08-11 | $2.43M derived: sum of 3 quarters · filed 2023-08-11 | $5.71M derived: sum of 4 quarters · filed 2023-08-11 | |
| 2022-03-31 | $10.54M 10-Q · filed 2023-05-11 | $12.47M derived: sum of 2 quarters · filed 2023-05-11 | $15.75M derived: sum of 3 quarters · filed 2023-05-11 | $16.12M derived: sum of 4 quarters · filed 2023-05-11 | |
| 2021-12-31 | $1.93M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-22 | $5.21M derived: sum of 2 quarters · filed 2023-03-22 | $5.58M derived: sum of 3 quarters · filed 2023-03-22 | $5.09M 10-K · filed 2023-03-22 | |
| 2021-09-30 | $3.28M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-01 | $3.65M derived: sum of 2 quarters · filed 2022-11-01 | $3.16M 10-Q · filed 2022-11-01 | $3.95M derived: sum of 4 quarters · filed 2022-11-01 | |
| 2021-06-30 | $377.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-15 | -$114.00K 10-Q · filed 2022-08-15 | $668.00K derived: sum of 3 quarters · filed 2022-08-15 | ||
| 2021-03-31 | -$491.00K 10-Q · filed 2022-05-13 | $291.00K derived: sum of 2 quarters · filed 2022-05-13 | |||
| 2020-12-31 | $782.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-29 | $1.74M 10-K · filed 2022-03-29 | |||
| 2020-09-30 | $960.00K 10-Q · filed 2021-11-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |